Several in vitro studies showed promising effects of TKIs on systemic sclerosis (SSc), rheumatoid arthritis (RA) and other fibrotic diseases by inhibition of TGFβ and PDGF signaling [2], [3]. This evidence concerns the gene TGFB1 and systemic sclerosis.